Investigating how a protein called Bik affects the severity of influenza A virus infections
The role of Bik in the replication and severity of influenza A virus
This study is looking at how a protein called Bik affects the flu virus and lung problems, especially in cancer patients, to find new ways to help those who are more at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11000322 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the Bik protein in the replication of the influenza A virus (IAV) and its impact on respiratory illnesses, particularly in cancer patients. The study examines how deficiencies in Bik can lead to reduced viral replication and less severe lung inflammation, potentially improving survival rates after infection. By exploring the interactions between host cellular factors and the virus, the research aims to identify new therapeutic strategies to combat IAV, especially in vulnerable populations. The methodology includes using animal models and analyzing viral protein levels in infected cells to assess the effects of Bik on IAV.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are at increased risk for severe complications from influenza A virus infections.
Not a fit: Patients who do not have cancer or other underlying health conditions that increase their risk for severe influenza complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antiviral therapies that improve outcomes for patients, particularly those with compromised immune systems.
How similar studies have performed: Other research has shown promising results in targeting host cellular factors to inhibit viral replication, suggesting that this approach may be effective.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Mebratu, Yohannes Afework — Ohio State University
- Study coordinator: Mebratu, Yohannes Afework
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.